KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Other Accumulated Expenses (2016 - 2025)

Abbott Laboratories' Other Accumulated Expenses history spans 17 years, with the latest figure at $5.8 billion for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 13.01% year-over-year to $5.8 billion; the TTM value through Dec 2025 reached $5.8 billion, up 13.01%, while the annual FY2025 figure was $5.8 billion, 13.01% up from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $5.8 billion at Abbott Laboratories, down from $5.9 billion in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $5.9 billion in Q3 2025 and bottomed at $5.1 billion in Q2 2024.
  • The 5-year median for Other Accumulated Expenses is $5.4 billion (2022), against an average of $5.5 billion.
  • The largest annual shift saw Other Accumulated Expenses rose 27.29% in 2021 before it dropped 9.34% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $5.2 billion in 2021, then grew by 12.82% to $5.8 billion in 2022, then dropped by 7.24% to $5.4 billion in 2023, then fell by 5.15% to $5.1 billion in 2024, then increased by 13.01% to $5.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Other Accumulated Expenses are $5.8 billion (Q4 2025), $5.9 billion (Q3 2025), and $5.7 billion (Q2 2025).